鶹ý

GIP/GLP-1 RA Phase III Success; USPSTF Looking for Input

— News and commentary from the endocrinology world

MedpageToday
ENDOBREAK centered between 8 illustrated body organs.

Eli Lilly said the SURPASS-3 and SURPASS-5 phase III clinical trials showed that the once-weekly significantly reduced HbA1c and body weight in adults with type 2 diabetes -- meeting both trials' primary and key secondary endpoints.

In other trial success, the SKYLIGHT 1 and SKYLIGHT 2 phase III clinical trials also met all their primary endpoints with the investigational, oral, for moderate to severe vasomotor symptoms of menopause, Astellas announced.

tended to have higher levels of certain hormones like follicle-stimulating hormone, inhibin B, and testosterone during puberty compared with normal weight girls. "In some girls with higher total body fat, higher testosterone levels were associated with irregular menstrual cycles, acne, and excess body hair," added study author Natalie Shaw, MD, of the National Institute of Environmental Health Sciences, in a statement. (Journal of Clinical Endocrinology & Metabolism)

The U.S. Preventive Services Task Force is asking for comments through March 15 on its draft recommendation statement on screening for .

USPSTF is also seeking comments on a draft research plan regarding for the primary prevention of chronic conditions in postmenopausal women, through March 17.

A Mendelian randomization study found that development. (ScienceDaily)

In a 20-year follow-up study of , 11% experienced erythrocytosis, with the largest increases in hematocrit seen in the first year of hormone initiation. (Journal of Clinical Endocrinology & Metabolism)

A phase IIa clinical trial is in the works being led by Jennifer Miller, MD, of the University of Florida, to study an investigative , Tryp Therapeutics announced.

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.